Cargando…

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

Beyond classic “allergic”/atopic comorbidities, atopic dermatitis (AD) emerges as systemic disease with increased cardiovascular risk. To better define serum inflammatory and cardiovascular risk proteins, we used an OLINK high-throughput proteomic assay to analyze moderate-to-severe AD (n = 59) comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunner, Patrick M., Suárez-Fariñas, Mayte, He, Helen, Malik, Kunal, Wen, Huei-Chi, Gonzalez, Juana, Chan, Tom Chih-Chieh, Estrada, Yeriel, Zheng, Xiuzhong, Khattri, Saakshi, Dattola, Annunziata, Krueger, James G., Guttman-Yassky, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562859/ https://www.ncbi.nlm.nih.gov/pubmed/28821884 http://dx.doi.org/10.1038/s41598-017-09207-z

Ejemplares similares

Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
por: Brunner, Patrick M., et al.
Publicado: (2018)

Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
por: Ewald, David A., et al.
Publicado: (2015)

Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome
por: Kim, Madeline, et al.
Publicado: (2023)

Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020)

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
por: Ungar, Benjamin, et al.
Publicado: (2022)

Successful use of ustekinumab therapy in refractory severe atopic dermatitis
por: Shroff, Anjali, et al.
Publicado: (2014)

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics
por: Mansouri, Yasaman, et al.
Publicado: (2015)

Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis
por: Ruano, Juan, et al.
Publicado: (2016)

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment
por: Facheris, Paola, et al.
Publicado: (2023)

A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis
por: Dhingra, Nikhil, et al.
Publicado: (2014)

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches
por: Moyle, Matthew, et al.
Publicado: (2019)

Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis
por: Dhingra, Nikhil, et al.
Publicado: (2013)

Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity
por: Vekaria, Anjali S., et al.
Publicado: (2017)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus
por: Abuabara, K., et al.
Publicado: (2021)

Atopic Dermatitis: Epidemiology and Clinical Phenotypes
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
por: Olesen, Caroline Meyer, et al.
Publicado: (2021)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitis
por: Rizzo, J M, et al.
Publicado: (2016)

International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale
por: Abuabara, Katrina, et al.
Publicado: (2020)

RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing
por: Wu, Jianni, et al.
Publicado: (2020)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement
por: Leshem, Y.A., et al.
Publicado: (2019)

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
por: Eichenfield, Lawrence F., et al.
Publicado: (2022)

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
por: Callewaert, Chris, et al.
Publicado: (2019)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
por: Falissard, Bruno, et al.
Publicado: (2020)

IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model
por: Chiricozzi, Andrea, et al.
Publicado: (2014)

Apremilast as a treatment for morphea: A case series
por: Koschitzky, Merav, et al.
Publicado: (2021)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology
por: Paller, Amy S, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials
por: Paller, Amy S., et al.
Publicado: (2023)

Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?
por: Gaspar, Neide Kalil, et al.
Publicado: (2016)

The erythema Q‐score, an imaging biomarker for redness in skin inflammation
por: Frew, John, et al.
Publicado: (2020)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v5ca91u112caq1cc34dsb2adj8